Bullish
Bristol Myers deepens AI investment with Anthropic deal
Bristol Myers Squibb is expanding its use of artificial intelligence by partnering with Anthropic to deploy its Claude AI tool across its operations. ...
BMY
--
--
--
--
Price Chart (30 Days)
Ad Space
Analyst Sentiment
Bullish (25)
Neutral (21)
Bearish (2)
Latest BMY News
Bullish
Bullish
Bristol Myers Squibb announces strategic agreement with Anthropic
Bristol Myers Squibb (BMS) has entered into a strategic agreement with Anthropic to widely deploy Claude, an AI system, across its various functions i...
Bullish
Exclusive | Bristol-Myers Squibb Brings Anthropic’s Claude to 30,000 of Its Staff
Bristol-Myers Squibb is integrating Anthropic’s Claude AI product for over 30,000 employees to enhance its use of artificial intelligence across resea...
Neutral
Banque Cantonale Vaudoise Sells 25,225 Shares of Bristol Myers Squibb Company $BMY
Banque Cantonale Vaudoise reduced its stake in Bristol Myers Squibb (BMY) by 19.7% in Q4, selling 25,225 shares and retaining 102,547 shares valued at...
Bullish
Pharma giant considers Houston for $1B manufacturing campus
Bristol Myers Squibb Co. is considering Houston's Generation Park for a new $1 billion multi-modal pharmaceutical manufacturing campus, potentially cr...
Neutral
Bristol Myers Squibb Houston Plant Raises Questions On Value And Outlook
Bristol-Myers Squibb plans a US$1 billion pharmaceutical manufacturing facility in Houston, creating 500 jobs and expanding its US production. This in...
Bullish
Handelsbanken Fonder AB Has $68.50 Million Stake in Bristol Myers Squibb Company $BMY
Handelsbanken Fonder AB significantly increased its stake in Bristol Myers Squibb (NYSE:BMY) by 12.5% in the fourth quarter, bringing its total holdin...
Neutral
Bristol-Myers Squibb Made Its Pipeline Case at BofA. Now Comes the Proof.
Bristol-Myers Squibb (BMY) is facing patent cliffs and projected revenue decline, making its pipeline critical for future growth. Following a detailed...
Bullish
Bristol Myers Squibb Bolsters Oncology Pipeline with Lonza Licensing Agreement
Bristol Myers Squibb has entered into an exclusive single-target licensing agreement with Lonza, a CDMO, to advance an Antibody-Drug Conjugate (ADC) f...
Bullish
Leuthold Group LLC Buys New Stake in Bristol Myers Squibb Company $BMY
Leuthold Group LLC has acquired a new stake in Bristol Myers Squibb Company, purchasing 101,025 shares valued at approximately $5.45 million in the fo...
Bullish
ARS Investment Partners LLC Purchases 177,916 Shares of Bristol Myers Squibb Company $BMY
ARS Investment Partners LLC significantly increased its stake in Bristol Myers Squibb Company (NYSE:BMY) during the fourth quarter by purchasing an ad...
Neutral
Is Hengrui’s US$15.2 Billion Alliance Reshaping the Investment Case for Bristol Myers Squibb (BMY)?
Bristol Myers Squibb has formed a strategic collaboration with Hengrui Pharma, valued at up to $15.2 billion, to advance oncology, hematology, and imm...
Bullish
DNB Asset Management AS Boosts Holdings in Bristol Myers Squibb Company $BMY
DNB Asset Management AS increased its stake in Bristol Myers Squibb (NYSE:BMY) by 4.2% in the fourth quarter, bringing its total holdings to 733,347 s...
Bullish
BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal
Bristol Myers Squibb (BMS) and Hengrui Pharma have announced a massive collaboration to develop 13 investigational therapies for cancer, immune-mediat...
Bullish
Bristol Myers Squibb partners with China’s Hengrui Pharma on a dozen drugs
Bristol Myers Squibb has entered into a significant partnership with China's Hengrui Pharma, valued at up to $15.2 billion with a $600 million upfront...
Bristol-Myers Squibb (BMY): Buy, Sell, or Hold Post Q1 Earnings?
Bristol-Myers Squibb (BMY) has seen an impressive stock run, outperforming the S&P 500. However, the company's long-term revenue growth and EPS have b...
Neutral
Bristol-Myers Squibb Stock Slides -8.1% With A 7-Day Losing Spree
Bristol-Myers Squibb (BMY) stock experienced an 8.1% slide over a 7-day losing streak, resulting in a $10 billion reduction in its market capitalizati...
Bullish
Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology
Hengrui Pharma and Bristol Myers Squibb have announced global strategic collaboration and license agreements to advance 13 early-stage programs across...
Bullish
HENGRUI PHARMA (01276.HK) and Bristol-Myers Squibb Company (BMY.US) Enter Global Strategic Collaboration and License Agreement, Eligible for USD950 million in Related Payments
HENGRUI PHARMA has entered a global strategic collaboration and license agreement with Bristol-Myers Squibb Company (BMS) to advance 13 early-stage pr...
Bullish
China's Jiangsu Hengrui, Bristol Myers Squibb in deal worth up to $15.2 bln
China's Jiangsu Hengrui Pharmaceuticals has signed a global strategic collaboration and licensing deal with U.S. drugmaker Bristol Myers Squibb. The a...
Research BMY on:
Ad Space